The impact of CDK2 inhibition on cancer cells confirmed the validity of CDK2 as a promising anticancer drug target, therefore, many CDK2 inhibitors have been progressed through clinical trials (Figure 1)34,35,.38 Here, CDK2 is linked to cancer.